Learn about real-world data and its applications in oncology

Researchers from the National Cancer Institute and Flatiron Health used real-world data to examine treatment patterns, toxicity and clinical outcomes of immune checkpoint-inhibitor treated patients with advanced melanoma and organ dysfunction.

To further understand the association between FDA approvals of immune checkpoint inhibitors and treatment patterns at the end of life, researchers utilized real-world data to examine treatment patterns at the EOL for patients with advanced melanoma, non-small cell lung cancer or microsatellite stable colon cancer.

This paper examines the impact of an FDA alert and label change on clinical practice using real-world data obtained from electronic health records.

In this study, researchers from the FDA and Flatiron Health applied their method for assessing disease progression in real-world cancer datasets to a large cohort of patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors: nivolumab, pembrolizumab, and atezolizumab.

This abstract sought to look at the correlation between Medicaid expansion under the Affordable Care Act and racial disparities in timely cancer treatment using data collected from EHRs.

Co-authored with the FDA, this study analyzed a large and recent real-world cohort to estimate real-world survival following treatment with PD-1 inhibitors, nivolumab and pembrolizumab, in the first year following regulatory approval for NSCLC.